The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder

被引:21
|
作者
Friesen, Erik Loewen [1 ,2 ,3 ]
Kurdyak, Paul [1 ,3 ,4 ]
机构
[1] Univ Toronto, Inst Hlth Policy Management & Evaluat, 155 Coll St 4th Floor, Toronto, ON M5T 3M6, Canada
[2] Univ Toronto, Fac Med, Toronto, ON, Canada
[3] Ctr Addict & Mental Hlth, Toronto, ON, Canada
[4] ICES, Toronto, ON, Canada
关键词
Opioid use disorder; Psychiatry; Mental health; Medication for opioid use disorder; Treatment discontinuation; SUBSTANCE USE; TREATMENT COMPLETION; BUPRENORPHINE/NALOXONE TREATMENT; METHADONE; PREDICTORS; DEPENDENCE; DISPARITIES; ATTRITION; EPIDEMIC; DROPOUT;
D O I
10.1016/j.drugalcdep.2020.108244
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Psychiatric illness complicates the clinical course of opioid use disorder (OUD) including treatment using medication for OUD (MOUD). The purpose of this study was to assess the relationship between psychiatric comorbidity and MOUD discontinuation, stratified by whether the client dropped out of treatment or whether MOUD was terminated by the addiction facility. Methods: The study population consisted of individuals with OUD receiving MOUD. Data was derived from the 2015-2017 Treatment Episodes Dataset - Discharges (TEDS-D), which includes discharge records from addiction treatment centers across the United States. The association between psychiatric comorbidity and MOUD discontinuation (including client dropout and facility termination) was assessed using multivariable logistic regression models that included clinically relevant covariates (age, sex, race, education, employment status, living arrangement, prior addiction treatment, intravenous opioid use, primary opioid used at admission, polysubstance use, previous arrests, length of stay, and referral source). Results: Psychiatric comorbidity decreased the odds of client dropout (adjusted odds ratio (aOR): 0.88, 95 % confidence interval (CI): 0.86 - 0.89) but increased the odds of MOUD being terminated by the treatment facility (aOR: 1.59, 95 % CI: 1.56-1.63). The association between psychiatric comorbidity and MOUD discontinuation varied considerably between states. Conclusions: Individuals with psychiatric illness are slightly less likely to drop out of MOUD treatment but are more likely to have their treatment prematurely terminated by the treatment facility. This emphasizes the importance of considering psychiatric illness when providing OUD treatment and suggests that measures to improve MOUD retention for individuals with psychiatric illness are required.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Alcohol Use Among Treatment-Seeking Individuals With Opioid Use Disorder
    Baskerville, Wave-ananda
    Grodin, Erica N.
    Lin, Johnny
    Miotto, Karen
    Mooney, Larissa J.
    Ray, Lara A.
    JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2023, 84 (04) : 579 - 584
  • [22] Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder
    Ellis, Matthew S.
    Xu, Kevin Y.
    Tardelli, Vitor S.
    Fidalgo, Thiago M.
    Buttram, Mance E.
    Grucza, Richard A.
    JAMA PSYCHIATRY, 2023, 80 (12) : 1269 - 1276
  • [23] ALCOHOL USE AMONG TREATMENT-SEEKING INDIVIDUALS WITH OPIOID USE DISORDER
    Baskerville, W.
    Grodin, E. N.
    Lin, J.
    Miotto, K.
    Mooney, L.
    Ray, L. A.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 222A - 222A
  • [24] PAIN AND OPIOID PRESCRIPTIONS AS PREDICTORS OF OPIOID USE DISORDER AMONG INDIVIDUALS IN ALCOHOL TREATMENT
    Leonard, K.
    Falls, Z.
    Jacobs, D.
    Gibson, W.
    Bednzarczyk, E.
    Jette, G.
    Elkin, P. L.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 22A - 22A
  • [25] Medications for Opioid Use Disorder Among Incarcerated Individuals: a Review of the Literature and Focus on Patient Preference
    Lisa B. Puglisi
    Precious S. Bedell
    Anna Steiner
    Emily A. Wang
    Current Addiction Reports, 2019, 6 : 365 - 373
  • [26] Medications for Opioid Use Disorder Among Incarcerated Individuals: a Review of the Literature and Focus on Patient Preference
    Puglisi, Lisa B.
    Bedell, Precious S.
    Steiner, Anna
    Wang, Emily A.
    CURRENT ADDICTION REPORTS, 2019, 6 (04) : 365 - 373
  • [27] Management of Critically Ill Patients Receiving Medications for Opioid Use Disorder
    Erstad, Brian L.
    Glenn, Melody J.
    CHEST, 2024, 165 (02) : 356 - 367
  • [28] Breastfeeding Motivators and Barriers in Women Receiving Medications for Opioid Use Disorder
    Yonke, Nicole
    Yakes Jimenez, Elizabeth
    Leeman, Lawrence
    Leyva, Yuridia
    Ortega, Alyssa
    Bakhireva, Ludmila N.
    BREASTFEEDING MEDICINE, 2020, 15 (01) : 17 - 23
  • [29] An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals
    Al Faysal J.
    Noor-E-Alam M.
    Young G.J.
    Lo-Ciganic W.-H.
    Goodin A.J.
    Huang J.L.
    Wilson D.L.
    Park T.W.
    Hasan M.M.
    Computers in Biology and Medicine, 2024, 177
  • [30] Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family
    Chatterjee, Avik
    Yu, Eun Jin
    Tishberg, Lindsay
    DRUG AND ALCOHOL DEPENDENCE, 2018, 188 : 161 - 168